Property | Value |
?:abstract
|
-
There is currently no approved pharmaceutical product for the treatment of COVID-19. However, antibiotics are currently being used for the management of COVID-19 patients in many settings either treat to co-infections or for the treatment of COVID-19 itself. In this commentary, we highlight that the increased rates of antimicrobial prescribing for COVID-19 patients could further worsen the burden of antimicrobial resistance (AMR). We also highlight that though AMR is a global threat, Africa tends to suffer most from the consequences. We, therefore, call on African countries not to lose sight of the possible implications of the treatment of COVID-19 on AMR and a need to redouble efforts towards the fight against AMR while dealing with the pandemic.
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
-
10.11604/pamj.supp.2020.35.23713
|
?:doi
|
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/a953e06477682e8a4a3e4629b9e65f302f4d60dc.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7687464.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
is
?:relation_isRelatedTo_publication
of
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
Treatment of COVID-19: implications for antimicrobial resistance in Africa
|
?:type
|
|
?:year
|
|